Published in Tumour Biol on September 09, 2002
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer (2006) 2.70
The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol (2013) 2.65
Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene (2010) 2.10
MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene (2011) 1.86
Mucin-bacterial interactions in the human oral cavity and digestive tract. Gut Microbes (2010) 1.65
Mucin characteristics of human corneal-limbal epithelial cells that exclude the rose bengal anionic dye. Invest Ophthalmol Vis Sci (2006) 1.62
A binding domain on mesothelin for CA125/MUC16. J Biol Chem (2008) 1.61
Membrane-tethered mucins have multiple functions on the ocular surface. Exp Eye Res (2010) 1.54
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer (2010) 1.30
Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One (2011) 1.26
The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol Rev (2014) 1.21
Current status of mucins in the diagnosis and therapy of cancer. Biofactors (2009) 1.17
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer (2009) 1.13
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer (2014) 1.10
MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation (2008) 1.07
A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer (2011) 1.06
Characterization of a carbohydrate epitope defined by the monoclonal antibody H185: sialic acid O-acetylation on epithelial cell-surface mucins. Glycobiology (2006) 1.02
CA125/MUC16 is dispensable for mouse development and reproduction. PLoS One (2009) 0.98
Mucin 16 is a functional selectin ligand on pancreatic cancer cells. FASEB J (2011) 0.96
Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16. Appl Immunohistochem Mol Morphol (2010) 0.93
The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res (2010) 0.92
Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer (2011) 0.89
Epigenetic regulation of mucin genes in human cancers. Clin Epigenetics (2011) 0.89
MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression. BMC Cancer (2014) 0.88
Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells. Oncotarget (2015) 0.86
A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care. Cancer Prev Res (Phila) (2014) 0.83
Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther (2009) 0.83
MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling. Am J Cancer Res (2014) 0.82
Deciphering the molecular nature of ovarian cancer biomarker CA125. Int J Mol Sci (2012) 0.82
The mucin MUC16 (CA125) binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and preeclampsia. Am J Reprod Immunol (2012) 0.82
Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy. Cancer Res (2015) 0.79
Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer (2015) 0.79
Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments. Sci Rep (2015) 0.79
Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB. Oncotarget (2016) 0.77
Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement. Oncotarget (2017) 0.77
MUC16/CA125 in the context of modular proteins with an annotated role in adhesion-related processes: in silico analysis. Int J Mol Sci (2012) 0.75
The Spl Serine Proteases Modulate Staphylococcus aureus Protein Production and Virulence in a Rabbit Model of Pneumonia. mSphere (2016) 0.75
Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling). Biomolecules (2016) 0.75
C-terminus of MUC16 activates Wnt signaling pathway through its interaction with β-catenin to promote tumorigenesis and metastasis. Oncotarget (2016) 0.75
Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol (2004) 1.14
Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep (2005) 1.07
The transmembrane protease serine (TMPRSS3/TADG-12) D variant: a potential candidate for diagnosis and therapeutic intervention in ovarian cancer. Tumour Biol (2004) 0.88
High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma. Br J Haematol (2002) 0.86
Expression of human kallikrein 7 (hK7/SCCE) and its inhibitor antileukoprotease (ALP/SLPI) in uterine endocervical glands and in cervical adenocarcinomas. Oncol Rep (2004) 0.84
Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncol Rep (2004) 0.80
Expression of matrix metalloproteinases-2 and -9 by cells isolated from the peritoneal fluid of women with ovarian carcinoma. Acta Cytol (2002) 0.80
Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neoadjuvant chemotherapy. Int J Mol Med (2003) 0.79
GnRH agonist inhibits human telomerase reverse transcriptase mRNA expression in endometrial cancer cells. Int J Mol Med (2002) 0.78
Expression and epitope characterization of a recombinant CA 125 repeat: fourth report from the ISOBM TD-1 workshop. Tumour Biol (2009) 0.77
Expression of tumor-associated differentially expressed Gene-14 (TADG-14/KLK8) and its protein hK8 in uterine endometria and endometrial carcinomas. Tumour Biol (2006) 0.77
Telomerase activation in endometrial epithelial cells by paracrine effectors from stromal cells in primary cultured human endometrium. Int J Mol Med (2004) 0.76
Tumor dihydropyrimidine dehydrogenase activity in advanced cervical carcinoma. Oncol Rep (2002) 0.75
Endometrial cytodiagnosis using a new softcyte versus a conventional endocyte. Oncol Rep (2002) 0.75